These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2676339)

  • 21. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.
    Yan Z
    Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crossover design and its application in late-phase diabetes studies.
    Wang T; Malone J; Fu H; Heilmann C; Qu Y; Huster WJ
    J Diabetes; 2016 Sep; 8(5):610-8. PubMed ID: 27100270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carryover and the two-period crossover clinical trial.
    Willan AR; Pater JL
    Biometrics; 1986 Sep; 42(3):593-9. PubMed ID: 3567292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underestimation of treatment effect in crossover trials.
    Cleophas TJ
    Angiology; 1990 Sep; 41(9 Pt 1):673-80. PubMed ID: 2221469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The analysis of failure time data in crossover studies.
    France LA; Lewis JA; Kay R
    Stat Med; 1991 Jul; 10(7):1099-113. PubMed ID: 1876798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of two-treatment, two-period crossover trials in emergency medicine.
    Reed JF
    Ann Emerg Med; 2004 Jan; 43(1):54-8. PubMed ID: 14707941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CrossOver: an algorithm for the construction of efficient cross-over designs.
    John JA; Russell KG; Whitaker D
    Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On variance estimation in crossover designs.
    Kunert J
    Biometrics; 1987 Dec; 43(4):833-45. PubMed ID: 3427168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
    Liang Y; Carriere KC
    Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical properties of randomization in clinical trials.
    Lachin JM
    Control Clin Trials; 1988 Dec; 9(4):289-311. PubMed ID: 3060315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multivariate nonparametric analysis for the two-period crossover design with application in clinical trials.
    Johnson WD; Grender JM
    J Biopharm Stat; 1993 Mar; 3(1):1-12. PubMed ID: 8485530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of two-period crossover design in a multicenter clinical trial.
    Castellana JV; Patel HI
    Biometrics; 1985 Dec; 41(4):969-77. PubMed ID: 3830261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Eur J Clin Chem Clin Biochem; 1997 Oct; 35(10):775-9. PubMed ID: 9368796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crossover design in pharmacy research.
    Cody RL; Slack MK
    Ann Pharmacother; 1992 Mar; 26(3):327-33. PubMed ID: 1532519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limitations of randomized clinical trials. Proposed alternative designs.
    Cleophas TJ; Zwinderman AH
    Clin Chem Lab Med; 2000 Dec; 38(12):1217-23. PubMed ID: 11205684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of alternative statistical models for crossover studies to demonstrate caffeine adjuvancy in the treatment of tension headache.
    Koch GG; Amara IA; MacMillan J
    J Biopharm Stat; 1994 Nov; 4(3):347-410. PubMed ID: 7881452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal and/or efficient three treatment crossover designs for five carryover models.
    Gondaliya J; Divecha J
    J Biopharm Stat; 2020 May; 30(3):445-461. PubMed ID: 31721628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.